Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OliPass-VEGF
- Development stage
- Preclinical
- Lead developer
- OliPass
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Ophthalmic
01
Overview
OliPass-VEGF is an antisense oligonucleotide (ASO) therapeutic candidate being developed by OliPass for the treatment of retinal vascular diseases, including Age-related Macular Degeneration (AMD) and Diabetic Retinopathy (DR). Utilizing OliPass's proprietary Peptide Nucleic Acid (PNA) platform, the drug is designed to be administered as a topical eye drop, offering a potentially less invasive alternative to standard-of-care intravitreal injections. The therapeutic mechanism involves exon skipping of the Vascular Endothelial Growth Factor (VEGF) pre-mRNA, which selectively inhibits the expression of pro-angiogenic VEGF isoforms, thereby reducing pathological neovascularization and vascular leakage in the eye.
- Other names
- OliPass VEGF-ASOVEGF PNA antisense oligonucleotide
02
Targets
Beyond the preview
Go deeper on OliPass-VEGF.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OliPass-VEGF.